Purple Biotech Ltd.
NASDAQ:PPBT
2.33 (USD) • At close July 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0.196 | 0 | 0 | 1 | 1 | 1 | 0.1 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.196 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0 | -0 | -0 | 1 | 1 | 1 | 0.1 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | -0.001 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 7.62 | 17.034 | 16.32 | 11.827 | 7.488 | 2.278 | 5.268 | 4.64 | 4.18 | 2.56 | 3.192 | 0.109 |
| General & Administrative Expenses
| 2.935 | 4.844 | 5.962 | 5.821 | 5.708 | 6.078 | 5.188 | 6.388 | 3.001 | 1.508 | 1.269 | 1.061 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 2.935 | 4.844 | 5.962 | 5.821 | 5.708 | 6.078 | 5.188 | 6.388 | 3.001 | 1.508 | 1.269 | 1.061 |
| Other Expenses
| 0.45 | 0.393 | 0.321 | 0.012 | 0.293 | 0.356 | 0 | 1.033 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 11.005 | -22.467 | 22.603 | 17.934 | 13.239 | 8.752 | 8.826 | 12.061 | 7.183 | 4.069 | 5.181 | 1.17 |
| Operating Income
| -11.005 | -22.271 | -22.603 | -17.934 | -13.239 | -7.156 | -7.826 | -11.966 | -7.183 | -4.069 | -5.181 | -2.553 |
| Operating Income Ratio
| 0 | -113.741 | 0 | 0 | -13.239 | -7.156 | -7.826 | -119.66 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.726 | 2.294 | 0.843 | 0.108 | -15.462 | 1.479 | 2.257 | -1.042 | -4.942 | -0.133 | -0.071 | -0.075 |
| Income Before Tax
| -7.279 | -19.977 | -21.76 | -17.826 | -28.701 | -5.893 | -5.569 | -12.913 | -12.125 | -4.202 | -5.252 | -2.628 |
| Income Before Tax Ratio
| 0 | -102.025 | 0 | 0 | -28.701 | -5.893 | -5.569 | -129.13 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0.216 | 0 | 0 | 0.006 | 0 | 0 | 0 |
| Net Income
| -7.24 | -0.02 | -21.668 | -18.384 | -27.999 | -5.85 | -5.2 | -12.177 | -12.125 | -4.202 | -5.252 | -2.628 |
| Net Income Ratio
| 0 | -0.102 | 0 | 0 | -27.999 | -5.85 | -5.2 | -121.77 | 0 | 0 | 0 | 0 |
| EPS
| -0.028 | -0.16 | -0.23 | -0.21 | -0.35 | -0.59 | -0.7 | -2.65 | -4.38 | -8.75 | -48.05 | -61.26 |
| EPS Diluted
| -0.028 | -0.16 | -0.23 | -0.21 | -0.35 | -0.59 | -0.7 | -2.65 | -4.38 | -8.75 | -48.05 | -61.26 |
| EBITDA
| -7.052 | -22.225 | -21.492 | -17.516 | -28.41 | -7.638 | -5.553 | -12.883 | -7.043 | -4.198 | -5.231 | -1.197 |
| EBITDA Ratio
| 0 | -113.506 | 0 | 0 | -28.41 | -7.638 | -5.553 | -128.83 | 0 | 0 | 0 | 0 |